Home/Filings/4/0001062993-23-015058
4//SEC Filing

NEWLIN WILLIAM R 4

Accession 0001062993-23-015058

CIK 0001842939other

Filed

Jul 17, 8:00 PM ET

Accepted

Jul 18, 8:37 PM ET

Size

12.2 KB

Accession

0001062993-23-015058

Insider Transaction Report

Form 4
Period: 2023-07-14
Transactions
  • Award

    Stock Option (right to buy)

    2023-07-14+108,167108,167 total
    Exercise: $2.11Exp: 2031-09-23Common Stock (108,167 underlying)
  • Other

    Common Stock Warrants

    2023-07-14+35,30435,304 total(indirect: By LLC)
    Exercise: $2.39Exp: 2032-09-30Common Stock (35,304 underlying)
  • Other

    Common Stock Warrants

    2023-07-14+482482 total(indirect: By LLC)
    Exercise: $6.71Exp: 2024-09-30Common Stock (482 underlying)
Holdings
  • Common Stock

    (indirect: By LLC)
    1,249,062
Footnotes (5)
  • [F1]Mr. Newlin is Chairman and Founder of Newlin Investment 1 LLC. By virtue of this relationship, Mr. Newlin may be deemed to share beneficial ownership of the securities held of record by Newlin Investment 1 LLC. Mr. Newlin disclaims any such beneficial ownership except to the extent of his pecuniary interest.
  • [F2]Options to purchase 108,167 shares of common stock of Legacy Carmell (as defined below) granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2021 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
  • [F3]On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.
  • [F4]These warrants are currently exercisable.
  • [F5]As part of the Business Combination, (i) existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation and (ii) existing Series C-1 warrants to purchase common stock of Legacy Carmell were exchanged for 0.06684 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.

Issuer

ALPHA HEALTHCARE ACQUISITION CORP III

CIK 0001842939

Entity typeother

Related Parties

1
  • filerCIK 0001076972

Filing Metadata

Form type
4
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 8:37 PM ET
Size
12.2 KB